Diplomat Pharmacy (NYSE:DPLO) was downgraded by research analysts at Raymond James from an “outperform” rating to a “market perform” rating in a research report issued to clients and investors on Monday, The Fly reports.
A number of other equities research analysts have also recently commented on DPLO. Barclays cut Diplomat Pharmacy from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $7.00 to $3.00 in a research report on Wednesday, November 13th. Wells Fargo & Co increased their price target on Diplomat Pharmacy from $5.00 to $5.50 and gave the stock a “market perform” rating in a research report on Tuesday, August 13th. ValuEngine lowered Diplomat Pharmacy from a “strong-buy” rating to a “buy” rating in a report on Thursday. Zacks Investment Research lowered Diplomat Pharmacy from a “hold” rating to a “sell” rating in a report on Friday, November 15th. Finally, Deutsche Bank began coverage on Diplomat Pharmacy in a research report on Thursday, September 12th. They issued a “sell” rating and a $4.00 price objective for the company. Four equities research analysts have rated the stock with a sell rating, ten have given a hold rating and one has assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $8.69.
DPLO opened at $5.81 on Monday. The firm has a fifty day moving average price of $5.00 and a 200 day moving average price of $5.24. Diplomat Pharmacy has a 1 year low of $2.43 and a 1 year high of $16.35. The stock has a market cap of $441.41 million, a P/E ratio of 29.05 and a beta of 0.92. The company has a debt-to-equity ratio of 0.18, a current ratio of 0.55 and a quick ratio of 0.36.
A number of large investors have recently bought and sold shares of the business. Royal Bank of Canada lifted its position in shares of Diplomat Pharmacy by 184.8% in the second quarter. Royal Bank of Canada now owns 4,782 shares of the company’s stock valued at $29,000 after acquiring an additional 3,103 shares in the last quarter. KBC Group NV purchased a new position in Diplomat Pharmacy in the 2nd quarter valued at $46,000. Man Group plc purchased a new position in Diplomat Pharmacy in the 3rd quarter valued at $51,000. Bank of Montreal Can boosted its stake in Diplomat Pharmacy by 138.4% during the 2nd quarter. Bank of Montreal Can now owns 11,444 shares of the company’s stock worth $70,000 after purchasing an additional 6,644 shares during the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. acquired a new stake in Diplomat Pharmacy during the 2nd quarter worth $77,000. Institutional investors own 84.14% of the company’s stock.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
Further Reading: Trading based on a resistance level
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.